Neurizon Therapeutics Limited (ASX:NUZ)
Australia
· Delayed Price · Currency is AUD 0.0850
-0.0020 (-2.30%)
Apr 29, 2026, 3:47 PM AEST
Neurizon Therapeutics Revenue
Neurizon Therapeutics had revenue of 5.97M AUD in the half year ending December 31, 2025, with 596.70% growth. This brings the company's revenue in the last twelve months to 5.98M, up 294.48% year-over-year. In the fiscal year ending June 30, 2025, Neurizon Therapeutics had annual revenue of 1.54M with 82.70% growth.
Revenue (ttm)
5.98M
Revenue Growth
+294.48%
P/S Ratio
10.80
Revenue / Employee
1.49M
Employees
4
Market Cap
64.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.54M | 696.12K | 82.70% |
| Jun 30, 2024 | 841.71K | -31.94K | -3.66% |
| Jun 30, 2023 | 873.65K | -3.64M | -80.63% |
| Jun 30, 2022 | 4.51M | 853.24K | 23.33% |
| Jun 30, 2021 | 3.66M | -463.19K | -11.24% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Prescient Therapeutics | 4.27M |
| Entropy Neurodynamics | 1.58M |
| Radiopharm Theranostics | 16.28M |
| LTR Pharma | 1.13M |
| Cynata Therapeutics | 1.69M |
| Botanix Pharmaceuticals | 21.92M |
| Amplia Therapeutics | 5.01M |
| Paradigm Biopharmaceuticals | 8.45K |
Neurizon Therapeutics News
- 2 months ago - Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial - PRNewsWire
- 4 months ago - FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial - PRNewsWire